Respiratory Diseases
2023 Activity indicators
- 1 European competitive public project led: HE MORPHEUS
- 4 competitive public led projects: ISCIII
- 2 competitive private projects led: Merck Health & Caixa Research Health
- 9 led clinical trials
- 37 publications
- IF: 281.11
- Q1 publications: 27 (73%)
- D1 publications: 4 (11%)
- 3 thesis
- 1 research award for the best international publication
- 1 consensus document
- Project and scientific communications evaluators: 1 PI
- Members of editorial committees: 1 PI
Milestones
- Dr. Jiménez has acted as Coordinator of the Care Process for the Management of Pulmonary Thromboembolism (PE) in the Community of Madrid. He has also been recognized as the second world expert in the management of PE.
- Achievement of the first competitive European project led by the research group: "MORPHEUS. Prognosis improvement of unprovoked venous thromboembolism using personalized anticoagulant therapy". Requested and granted in the HORIZON-HLTH-2022-TOOL-11 call and funded by the Horizon Europe Research Framework Program.
- Achievement of the first CaixaResearch Health grant from the "la Caixa" Foundation at the IRYCIS to finance the project "Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism. ROPE clinical trial". Project to evaluate whether the administration of supplemental oxygen improves the prognosis of patients with pulmonary thromboembolism.
- Defense of three new doctoral theses by members of the research group, which have been awarded Outstanding Cum Laude and which address pulmonary thromboembolism from different perspectives.
- The research group is simultaneously developing three research projects from the National Plan (ISCIII) call, led by Dr. Irene Cano (PI22/01688), Dr. David Jiménez (PI20/00369) and Dr. Deisy Barrios (PI18/00172).
Bibliometrics
Articles | Accum. IF | Mean IF | Articles Q1 or Q2 | % in Q1 or Q2 | Articles D1 | % in D1 | |
---|---|---|---|---|---|---|---|
2019 | 56 | 315.53 | 5.63 | 41 | 73 | 11 | 20 |
2020 | 61 | 414.66 | 6.80 | 51 | 84 | 16 | 26 |
2021 | 51 | 497.78 | 9.76 | 58 | 114 | 13 | 25 |
2022 | 50 | 490.70 | 9.81 | 46 | 92 | 15 | 30 |
2023 | 37 | 281.11 | 7.60 | 31 | 84 | 4 | 11 |
255 | 1999.78 | 7.92 | 212 | 83 | 59 | 23 |
*Only original articles, editorials, guidelines and reviews